Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age

• Published in: Journal of comparative effectiveness research Vol. 10; no. 15; pp. 1121 - 1131
• Main Authors: Caplan, Eleanor O, Patel, Anisha M, DeClue, Richard W, Sehman, Marina, Cornett, Daniel, Shaffer, Tiffany Fair, Raimundo, Karina, Suehs, Brandon T
• Format: Journal Article
• Language: English
• Published: Future Medicine Ltd 01.10.2021
• Subjects: delivery of healthcare; factor VIII; hemophilia A; hemorrhage; therapeutics
• ISSN: 2042-6305; 2042-6313
• DOI: 10.2217/cer-2021-0109

Examine real-world characteristics, treatment patterns, and outcomes among treated persons with hemophilia A (PwHA) stratified by age. This study utilized US claims data from 1 January 2007–31 July 2018 from the Humana Research Database. Unadjusted comparisons were conducted across PwHA (<18, 18–55, 56–89 years) enrolled in commercial or Medicare Advantage Prescription Drug plans. A total of 294 PwHA were identified; 21.1% experienced ≥1 bleeding event, and 41.2 and 53.1% had evidence of arthropathy or related disorders, and pain, respectively. Along with all-cause and hemophilia-related healthcare resource utilization (HCRU), these were highest among PwHA aged 56–89 years. Insights into treatment, outcomes and HCRU may identify opportunities for enhanced disease management, particularly in older PwHA. New study from Caplan, examines real-world treatment characteristics, treatment patterns and outcomes in treated persons with hemophilia A, including older persons aged 56–89 years.